Literature DB >> 26802799

Robotic Level III IVC Tumor Thrombectomy: Duplicating the Open Approach.

Daniel Ramirez1, Matthew J Maurice2, Benjamin Cohen2, Venkatesh Krishnamurthi2, Georges-Pascal Haber2.   

Abstract

OBJECTIVES: To describe our surgical technique for robotic radical nephrectomy and thrombectomy for renal cell carcinoma and associated level III inferior vena cava (IVC) thrombus with retroperitoneal lymph node dissection.
METHODS: The patient is a 75-year-old Caucasian man with a 10-cm right renal neoplasm and associated level III tumor thrombus. After preoperative imaging was reviewed, a robotic approach was planned. Real-time intraoperative transesophageal ultrasonography was performed to assess the cranial extent of tumor thrombus. The major steps of our technique include early inter-aortocaval control of the right renal artery, circumferential mobilization of the IVC, contralateral renal vein control, cavotomy, thrombectomy, and reconstruction of the IVC.
RESULTS: Operative time was 5 hours and 53 minutes (353 minutes) with 150 mL estimated blood loss. The patient was allowed to have a clear liquid diet immediately after surgery and was discharged home on postoperative day 3. Final pathology demonstrated a 9.8-cm clear cell renal cell carcinoma, nuclear grade 3 with a pT3bN1 stage.
CONCLUSIONS: With adequate team experience and preparation, robotic radical nephrectomy and IVC tumor thrombectomy for level III tumor thrombus is challenging but feasible in select patients. Herein we describe our robotic technique which duplicates the open approach. This minimally invasive approach may offer lower estimated blood loss, improved pain control, and expedited recovery.
Copyright © 2016 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2016        PMID: 26802799     DOI: 10.1016/j.urology.2016.01.011

Source DB:  PubMed          Journal:  Urology        ISSN: 0090-4295            Impact factor:   2.649


  7 in total

1.  Optimization of blood loss during robotic IVC thrombectomy in a Jehovah's witness: a case report with 14-month follow up.

Authors:  Logan W McGuffey; Alexander B Jones; Naveen Pokala
Journal:  J Robot Surg       Date:  2017-09-01

Review 2.  Frontiers in robot-assisted retroperitoneal oncological surgery.

Authors:  Wesley W Ludwig; Michael A Gorin; Phillip M Pierorazio; Mohamad E Allaf
Journal:  Nat Rev Urol       Date:  2017-09-12       Impact factor: 14.432

Review 3.  Minimally invasive radical nephrectomy: a contemporary review.

Authors:  Akbar N Ashrafi; Inderbir S Gill
Journal:  Transl Androl Urol       Date:  2020-12

4.  Step-by-step and orderly lowering of the height of inferior vena cava tumor thrombus is the key to robot-assisted thrombectomy for Mayo III/IV tumor thrombus.

Authors:  Guo-Dong Zhao; Xiu-Ping Zhang; Ming-Gen Hu; Qing-Bao Huang; Shuai Xu; Bao-Jun Wang; Xin Ma; Xu Zhang; Wen-Bo Zou; Xuan Zhang; Zhi-Ming Zhao; Xiang-Long Tan; Sai Chou; Gang Wang; Rong Liu
Journal:  BMC Cancer       Date:  2022-02-07       Impact factor: 4.430

5.  Robot-assisted Level II-III Inferior Vena Cava Tumor Thrombectomy: Step-by-Step Technique and 1-Year Outcomes.

Authors:  Sameer Chopra; Giuseppe Simone; Charles Metcalfe; Andre Luis de Castro Abreu; Jamal Nabhani; Mariaconsiglia Ferriero; Alfredo Maria Bove; Rene Sotelo; Monish Aron; Mihir M Desai; Michele Gallucci; Inderbir S Gill
Journal:  Eur Urol       Date:  2016-09-20       Impact factor: 20.096

Review 6.  Robotic renal surgery for renal cell carcinoma with inferior vena cava thrombus.

Authors:  Selma Masic; Marc C Smaldone
Journal:  Transl Androl Urol       Date:  2021-05

7.  Pure retroperitoneal laparoscopic radical nephrectomy and thrombectomy with delayed occlusion of the proximal inferior vena cava (DOPI) technique for renal tumor with level II-III venous tumor thrombus.

Authors:  Zhuo Liu; Peng Hong; Guodong Zhu; Li Zhang; Xun Zhao; Shiying Tang; Feilong Yang; Xiaojun Tian; Guoliang Wang; Shudong Zhang; Hongxian Zhang; Yi Huang; Chunxia Liu; Cheng Liu; Lulin Ma
Journal:  BMC Cancer       Date:  2021-05-27       Impact factor: 4.430

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.